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ABSTRACT 
OBJECTIVES: Causes of death in Inflammatory Myopathies have rarely been studied. We have 
assessed a cohort of myositis patients followed in a single centre over a 37 year period  reviewing  
the mortality rate, causes of death and predictors of poor prognosis. 
METHODS: We performed a single-centre, retrospective study on patients aged ≥16 years fulfilling 
3 or 4 of the Bohan and Peter criteria, noting their demographic data, clinical features, serology, 
treatment and outcome. 
RESULTS: 97 patients were identified. 74.2% were females. The mean age at diagnosis was 40.5 
years (SD 13.2). 38.1% had adult-onset dermatomyositis, 36.1% adult-onset polymyositis and 
25.8% overlap myositis. 96.9% had upper and lower limb involvement (UL+/LL+) and 62.9% had a 
highest CK≥10 times the upper limit of normal. 33% had significant infection(s). The disease course 
was chronic persistent in 29.9%, relapsing and remitting in 34% and monophasic in 36.1%. All 
received steroids and 92.8% other immunosuppressant(s). The median follow-up was 9 years (IQR 
11.5). The estimated cumulative proportion survival at 5, 10, 15 and 20 years were 94.6%, 82.2%, 
72,1% and 66.1%, respectively. 24.7% of patients died, mostly due to infection (29.2%). In 
univariate analysis, lung involvement (HR 1.78, p=0.013), infection (HR 4.18, p=0.003) and UL+/LL+ 
(HR 0.13, p=0.010) were statistically significantly associated with the risk of death. In the 
multivariate analysis infection (HR 3.68, p=0.009) and UL+/LL+ (HR 0.16, p=0.027) were statistically 
significantly associated with survival. 
CONCLUSION: A good long-term survival is reported. Nevertheless, careful follow-up of myositis 
patients is important. 
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INTRODUCTION:  
Idiopathic inflammatory myopathies (IIM) are autoimmune systemic diseases characterized by 
chronic inflammation with progressive symmetrical mostly proximal muscle weakness, elevated 
serum muscle enzymes levels, electromyographic abnormalities and inflammatory infiltrates on 
muscle biopsy (1). The etiopathogenesis of IIM remains unknown, although environmental factors 
in genetically susceptible individuals are implicated (2). The classification of IIM can be divided into 
four main groups: adult onset polymyositis (APM), adult onset dermatomyositis (ADM), juvenile 
idiopathic inflammatory myopathies (JIIM) and inclusion body myositis (IBM) (3). It may be part of 
an overlap syndrome (OS), with other autoimmune diseases. The most common are systemic 
sclerosis, Sjögren’s syndrome, systemic lupus erythematosus (SLE), undifferentiated autoimmune 
rheumatic disease and rheumatoid arthritis. IIM, in particular ADM, can be associated with cancer 
in a paraneoplastic manner (3-4).   
Although muscle biopsy may not show inflammatory cell infiltrates in all cases, it is a valuable 
diagnostic tool that helps distinguishing different types of IIM and, along with clinical and 
serological features, may help predicting outcome (5). 
Since the 1950s corticosteroids have invariably been used, often with immunosuppressive drugs, 
notably   azathioprine, methotrexate, cyclosporine, cyclophosphamide and mycophenolate 
mofetil.  Intravenous immunoglobulin (IvIg) and rituximab are used in cases of refractory disease 
and to help minimize the steroid requirements (6). These drugs have clearly been helpful, but do 
expose these patients to increased risk of infection.  
Before corticosteroids and immunosuppressives were introduced, the mortality rate   was as high 
as 50-70% (7-10). Older series reported 5- year survival rates as low as 52% (11) or 65% (12), with 
survival rates at 7 and 8 years of 53% (12) and 72.8% (13). More recently, earlier diagnosis and 
more aggressive treatment regimens have improved the survival of these patients (9-10,14).  
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Malignancy, lung and cardiovascular complications as well as infections are the most common 
reported causes of death in these patients (3,7,8,10,14). However, the numbers of patients 
previously reported have often been quite small and the period of follow-up invariably < 15 years.  
We have carefully observed a cohort of myositis patients, followed in a single centre for a period 
of over 30 years. We now review the causes of death, survival and predictors of mortality. 
 
MATERIALS AND METHODS: 
We performed an observational retrospective study involving patients with IIM   followed up 
between January 1976 and December 2013. 97 patients with myositis, all under the care of one of 
us (DAI) were identified. Each fulfilled three or four of the Bohan and Peter criteria (1).  Those with 
a final diagnosis of IBM or muscular dystrophy were excluded from this study, as well as those 
with an age of onset < 16 years and patients whose follow-up was less than one year. Patients 
were divided into three groups: APM, ADM, and OS.  
From the patient’s medical notes we completed a database and analysed the demographic 
features (gender, ethnicity, age at diagnosis), duration of symptoms before diagnosis, extent of 
muscle involvement (ascertained by standard clinical assessment noting the presence or absence 
of upper and lower limb proximity muscles), autoantibody pattern, highest CK level, EMG and 
biopsy results, treatment, disease course and extramuscular involvement [heart, lung, 
gastrointestinal (GI) tract, joints, infections, malignancy, skin ulcers and calcinosis], time of follow-
up, date and cause of death. The extent of muscle involvement was divided into upper limb (UL) 
and/or lower limb (LL) involvement. The antinuclear antibody (ANA) was considered positive if the 
titre was ≥1:80 (by immunofluorescence). The results from a range of other autoantibodies were 
noted. We have been able to utilize stored serum from patients treated over 20 years ago for the 
more recently identified auto-antibodies. Serum CK level was considered abnormal when it 
exceeded the normal limit as defined by the local reference laboratory. Patients were divided into 
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5 groups according to levels of CK (table 1).  Cardiac involvement was defined by the presence (as 
a clinical manifestation or as a result of diagnostic tests) of one or more of the following: 
arrhythmia, conduction abnormalities, congestive heart failure, ischemic disease and valvulopathy. 
Pulmonary involvement was defined by persistent respiratory symptoms with abnormal 
pulmonary function tests, chest computed tomography scan features associated with interstitial 
lung disease (ILD), or pulmonary hypertension (diagnosed by echocardiography or right heart 
catheterization). GI involvement was defined as dysphagia, regurgitation or reflux. Joint 
involvement was considered to be present in patients with arthralgia or if an inflammatory ar-
thritis was diagnosed (on physical examination or by ultrasound scan). Significant infections were 
considered in patients with symptoms who needed hospitalization. Malignancy not linked to the 
IIM was considered in patients diagnosed more than two years after or before the diagnosis of 
myositis. Those in whom the malignancy was diagnosed within 2 years were included provided 
myositis specific autoantibodies were positive. The patients were classified into those who had a 
monophasic (M) illness (only one episode of active disease), a relapsing–remitting (RR) (disease 
flares and disease-free periods) and a chronic persistent (CP) disease (evidence of active disease 
despite treatment) (15). Disease activity was defined as a high serum CK together with symptoms 
suggestive of myositis or its complications.  Duration of symptoms was defined as the number of 
months since the symptoms started until the diagnosis was established. Duration of follow-up was 
defined as the number of years from the date of the diagnosis (time 0) to the date of the last visit 
to our department, to the end of observation period (December 2013) or to the date of death 
(endpoints). The cause of death was ascertained from a mixture of review of the patient’s hospital 
notes, general practitioner records and death certificates. 
 
Statistical analysis 
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The IBM® SPSS® Statistics Version 22 was used for statistical analysis.  The Kolmogorov-Smirnov 
test was used as test of normality.  Continuous variables with a distribution similar to normal were 
described by the mean and standard deviation (SD) and the remaining were described by the 
median and interquartile range (IQR) (P25-P75). Categorical variables were described by 
percentages. The 1-year survival rate was calculated by the direct method. The 5, 10, 15 and 20 
year survival rates were estimated using the Kaplan-Meier analysis. The Log rank test was used to 
determine the statistical significance of the differences in survival rates between the subgroups of 
each variable. The Cox proportional hazards regression was used to establish the relationship 
between the categorical predictor variables and the risk of death.  The independent variables 
shown to be statistically significant in univariate regression were further submitted to multivariate 
analysis.  The missing values were reported and excluded from the analysis. A p-value <0.05 was 
considered statistically significant.  
 
RESULTS: 
97 patients were assessed (Table 1). Most (74.2%) were females, with a female to male ratio of 
2.9, and most (63.9%) were Caucasian. The mean age at diagnosis was 40.5 years (SD 13.2). 44 
(45.4%) patients were diagnosed between the ages of 20 and 39 years old. The diagnosis was ADM 
in 37 (38.1%) patients, APM in 35 (36.1%), and OS in 25 (25.8%). For the 81 patients whose notes 
provided reliable information, the median duration of symptoms before the diagnosis was made 
was 6 months (IQR 9). In 26 (26.8%) patients the symptoms were present for less than 3 months 
before the diagnosis was made; 9 (9.3%) patients reported symptoms for at least 18 months 
before the diagnosis.  
In terms of clinical presentation, most patients (96.9%) had upper and lower limb involvement 
(UL+/LL+) while 1 had proximal weakness affecting only lower limbs (UL-/LL+) and 2 had no 
evidence of proximal weakness (UL-/LL-). Among the patients whose results were available, 47 
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(49%) were ANA positive, 22 (23.2%) had positive anti-synthethase antibodies (20 with anti-Jo1, 1 
with PL7 and 1 with PL12), SRP and Mi2 antibodies were positive in 3 (3.2%) and 5 (5.3%), 
respectively, and RNP was positive in 13 (13.7%). Most patients (62.9%) had a highest CK more 
than 10 times the upper limit of normal. Among those whose EMG and muscle biopsy reports 
were available (85 and 82 patients, respectively), these were compatible with an inflammatory 
myopathy in 89.4% and 85.4% of cases, respectively. The biopsy was normal in 11% and 
inconclusive in 3.6% of cases. In terms of extramuscular features, significant infection was 
reported in 32 (33%) patients, lung and GI complications were each reported in 31 (32%) patients, 
cardiac complications in 24 (24.7%), and malignancy in 12 (12.4%) (the prevalence of cancer was 
15.6% in ADM patients and 9.6% in APM patients). Furthermore, 45 (46.4%) patients had joint 
involvement, 8 (8.2%) had skin ulcers and 7 (7.2%) had calcinosis. Among the patients with 
malignancies, 4 were diagnosed within 2 years of the myositis diagnosis (all were female; 1 with 
ADM, positive ANA and Mi 2, who was diagnosed with Hodgkin Lymphoma (HL); 1 with ADM, Jo1 
positive, diagnosed with an endocrine carcinoma of the pancreas; 1 with OS, ANA and RNP 
positive, diagnosed with a HL; 1 with ADM, Jo1 positive, who had an endometrial carcinoma). The 
course of the disease was RR in 33 (34%), M in 35 (36.1%) and CP in 29 (29.9%). Therapeutically, all 
patients received steroids and most (92.8%) also received one or more immunosuppressive drugs. 
The ones more frequently used were azathioprine, methotrexate, cyclosporine, cyclophosphamide 
and IvIg.  
The median duration of follow-up was 9 years (IQR of 11.5 years). 20 (20.6%) patients were 
followed up for at least 20 years. The observed survival at 1 year was 100% and the estimated 
cumulative proportion survival at 5, 10, 15 and 20 years were 94.6%, 82.2%, 72,1% and 66.1%, 
respectively (Figure 1). During follow-up, 24 patients (24.7%) died, after a median follow up of 10 
years (IQR of 8.75 years). The mortality rate was 24.3% in ADM patients, 22.9% in APM and 28% in 
OS. Infection was the most common cause of death [n=7 (29.2%)]. Pneumonia was the most 
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frequent specific cause of death, being responsible for 20.8% of deaths in our cohort. Six patients 
(25%) died as a consequence of a malignancy, 4 (16.7%) died because of a cardiac complication 
and 2 (8.3%) because of a lung complication (Table 2). Among patients who died, most were 
females and Caucasian (58.3% and 66.7%, respectively). The mean age at diagnosis was 41.6 years 
(SD 14.6). Nine (37.5%) had ADM, 8   (33.3%) had APM and 7 (29.2%) had OS. The median duration 
of symptoms before diagnosis among these patients was 6 months (IQR 5.5). Most (91.6%) had 
involvement of upper and lower limb. Among the 23 patients whose results were available, ANA 
was positive in 14 (60.9%) and 8 (34.8%) had positive anti-synthetase antibodies. In 66.7% of 
patients who died, the highest CK was ≥ 10 times the upper limit of normal. A CP course was 
reported in 41.7% of these patients and the treatment included steroids+2 immunosuppressants 
in 33.3% (Table 1). 
There was no significant statistical difference in the risk of death between APM, ADM and OS 
patients, which led to their combination for survival analyses. Age, sex, ethnicity, disease course, 
CK level, ANA, antisynthetase antibodies , SRP ,Mi2 and RNP antibodies, treatment, delay in 
diagnosis, malignancy, cardiac, GI and joint involvement, skin ulcers and calcinosis were not 
statistically significantly related to the risk of death. In the univariate analysis, lung involvement 
[hazards ratio (HR) 1.78; 95% confidence interval (CI):1.13-2.82; p=0.013], infection (HR 4.18; 95% 
CI:1.61-10.91; p=0.003) and UL+/LL+ (HR 0.13; 95% CI:0.03-0.62; p=0.010) were statistically 
significantly associated with the risk of death. In the multivariate analysis, infection (HR 3.68; 95% 
CI:1.38-9.82; p=0.009) and UL+/LL+ (HR 0.16; 95% CI:0.03-0.81; p=0.027) were the only factors 
statistically significantly associated with survival. 
 
DISCUSSION: 
This study reports the longest follow up period of myositis patients that we are aware of (9,12,16-
19). We have focused on the number and causes of mortality in this group.  
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Our study population had a female preponderance (F:M ratio of 2.9), as previously reported in 
other series (9,13, 16-18,20-21). The mean age at onset was similar to that reported by Danko et 
al. (17) (40.5 and 39.2 years, respectively). In other reports, the mean age at onset was higher, 
varying between 45 and 52 years (13,18,20-21) or 56 years for polymyositis (PM) and 53 for 
dermatomyositis (DM) in another study (16). In terms of clinical presentation, most patients 
(97.9%) had evidence of proximal muscle weakness, with involvement of upper and lower limb in 
96.9%. Previous series (13,17,22) have reported evidence of proximal weakness in 80, 93 and 
100% of patients. Like in other studies (9,13,20,22), all of our patients received steroids. 93.3% 
also received other immunosuppressives, which is a higher percentage compared to that in other 
reports (13,20,22). While the early use of appropriate and aggressive immunosuppressive therapy 
is one of the factors contributing to an improved survival in IIM patients (17), it has been observed 
that steroid therapy predicts infection onset in APM/ADM, while other cytotoxic drugs amplify 
their immunosuppressive effects (23). Additionally, the incidence of malignant diseases may be 
increased by the long-term use of cytostatic drugs (16). Therefore, these patients must be closely 
monitored for extramuscular complications resulting from the disease and its treatment. 
In a small series of PM/DM patients (24), severe infections occurred in 26.1% of patients. Another 
study assessed the frequency of severe pyogenic and nonpyogenic/opportunistic infections, 
requiring hospitalization, in a large cohort (279 PM/DM patients) (23). Severe infections were 
reported in 37.3% of patients, most of them (68.3%) pyogenic (the majority aspiration 
pneumonia), but 35.7% were nonpyogenic/opportunistic infections, including infection by 
Mycobacterium tuberculosis and Candida albicans. In our study, significant infection(s) occurred in 
32 (33%) patients and lower respiratory tract infections (pneumonia, tracheobronchitis) were the 
most frequent. They were reported in 30 patients, 19 (63.3%) of whom had ILD. It is possible that 
pre-existent changes in the lung as well as the immunosuppressive treatment required for ILD 
creates a favorable environment for the development of pyogenic infections. Two patients had 
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septicemia, one of them of pulmonary origin and the other due to multiple infections (respiratory, 
urinary tract, pancreatic abscess). They were both on steroids and azathioprine and the second 
one had been treated with cyclophosphamide in the past. Two patients had articular tuberculosis. 
ILD was present in 32% of our cohort, a higher prevalence than that seen in previous reports 
(22.2%-23.1%) (17,25). In another study (26), the prevalence of ILD in PM and DM was 32%. These 
authors considered the possibility of selection bias caused by the severity of the disease in 
patients referred to specialized centers [like our own] and that patients with both clinical and 
subclinical disease were detected. This might also explain the high percentage of ILD in our cohort. 
In a systematic review (14), the incidence of cardiac involvement was 9 to 72% and heart failure 
was the most frequently reported symptom (32 to 77%). Cardiac involvement is also one of the 
most important causes of mortality in patients with DM, mainly due to congestive heart failure 
which is related to old age, metabolic syndrome and hypertension (5). In our study, 24 (24.7%) 
patients had cardiac involvement and, among these, 7 had heart failure and 11 had ischemic 
changes. It has been established that autoimmune disorders increase the risk of cardiovascular 
disease, which is not fully explained by traditional risk factors (27). It is possible that the chronic 
inflammation that occurs in inflammatory myopathies plays a role in the progression of coronary 
atherosclerosis (28). Nevertheless, among the patients with heart failure and/or ischemic changes, 
12 had a diagnosis of hypertension, diabetes and/or dyslipidemia. 
The risk of cancer is increased in patients with DM or PM (29-30), and the risk is higher in DM 
patients (25). The cancers most frequently reported in western countries are lung, breast, ovarian, 
pancreatic, colorectal and stomach (31-32). In our study, 12 (12.4%) patients were diagnosed with 
a malignancy and the prevalence was higher in ADM patients. The types of cancer were consistent 
with those previously reported. In 66.7% of patients with cancer, the malignancy was diagnosed 
more than two years apart from the myositis. This is in agreement with the previous observation 
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that, although the risk of cancer is higher in the first year after the diagnosis of the IIM, it is still 
higher than in the general population for more than five years (31). 
Our frequencies of GI involvement, calcinosis and skin ulcers are similar to what has been 
previously reported (9,17). 
Except for the study by Airio et al. (16), in which the median follow up was 11 years, our median 
time of follow up (9 years) is longer than that reported in most studies. (10,17-18,20-22]. 
Furthermore, a fifth (20.6%) of our cohort was followed up for at least 20 years. 
Similar to other reports (9,13), we did not find statistically significant difference in survival 
between APM, ADM and OS groups. Our survival rate for the whole group was 100% at 1 year and 
estimated cumulative survivals at 5, 10 and 15 years were 94.6%, 82.2% and 72.1%, respectively. 
Furthermore, we report an estimated survival rate at 20 years of 66.1%. Danko et al. (17) reported 
similar survival rates (95% at 1 year, 92% at 5 years and 89% at 10 years). These survival rates are 
higher than those reported in older series (11-13,19), reflecting the improvement in diagnostic and 
therapeutic management of myositis patients. In other recent series involving cancer associated 
myositis (9,18,21), survival rates were also lower than in our report. In the study by Airio et al. 
(16), the lower survival rates reported (75% and 55% for PM at 5 and 10 years, respectively; 63% 
and 53% for DM at 5 and 10 years, respectively) may be explained by a selection bias towards the 
severe end of the spectrum of myositis.  
Our mortality rate (24.7%) was similar to previous reports (9,33). Other studies also reported 
infections as the main [7,13] or as the second cause of death (10). In a study that analysed death 
certificates of DM/PM patients (8), infections were the fourth cause of death. Nevertheless, like in 
our study, pneumonia was the commonest specific cause of death, but it was included in the 
group of diseases of the respiratory system. Malignancies have been the main or one of the most 
frequent causes of death in some studies, particularly those including malignancy associated 
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myositis (7,9,20,22). Cardiac and lung involvement have also been described as common causes of 
death in other studies (9-10,13,17,21-22).  
Among the patients who died of pneumonia, one had a previous diagnosis of ILD, one (who died of 
aspiration pneumonia) had dysphagia, and another one had ILD and dysphagia. The extramuscular 
complications may have directly contributed to the cause of death of these patients. 
A number of unfavorable prognostic factors have been described in myositis: older age, male sex, 
longstandig symptoms before diagnosis, cardiac and lung involvement, presence of cancer, 
dysphagia, anti-synthetase and anti-SRP antibodies (9,13,16,19-20,24,34-37). In our series, in 
univariate analysis, infection (HR 4.18; 95% CI:1.61-10.91; p=0.003) and lung involvement (HR 
1.78; 95% CI:1.13-2.82; p=0.013) were statistically significantly associated with an increased risk of 
death. Previous studies (38-39) have noted a decreased survival in patients with ILD compared 
with those without ILD, which makes early detection of ILD a priority in these patients. In the 
multivariate analysis, patients with infections had a 3.68 greater probability of dying compared to 
those without infections (HR 3.68; 95% CI:1.38-9.82; p=0.009). We would emphasize the need for 
close monitoring of myositis patients in order to promptly diagnose and treat infections. Patients 
with both upper and lower limb involvement had a 84% lower probability of dying compared to 
other patients (HR 0.16; 95% CI:0.03-0.81; p=0.027). However, most patients [n=94 (96.9%)] had 
upper and lower limb involvement (23.4% of whom died) and, among the remaining 3 patients, 2 
(66.7%) died. This may represent a statistical bias that has contributed for this result. 
 Of note, the discrepancies regarding study designs, inclusion criteria and subgroups of IIM 
considered, make it difficult to compare results between different series. 
Our study is retrospective, observational and single-centre which may, nevertheless, have the 
advantage of a careful consistent approach to follow-up. Given the very long duration of follow-up 
we were not able in the study to utilize some of the more sophisticated methods of muscle 
weakness assessment. But all of these patients were examined repeatedly by the same observer 
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(DAI) over many years. The present study is one of the first to detail causes of death in patients 
with inflammatory muscle diseases followed for very long periods of time. Our observation period 
is longer than previously reported and our median follow up was higher than that reported in 
most studies.  Although the numbers are relatively small, our cohort has demonstrated multiple 
ethnicities. We report a good survival rate compared to other studies, over a follow up of ≥ 20 
years in many cases. Nevertheless, 24.7% of the patients died, the main cause being infection. 
Infection, malignancy, cardiac and lung involvement were, not only important causes of death, but 
also common extramuscular features of these patients, leading to a significant morbidity. This 
highlights the importance of a regular and careful follow up in these patients in order to promptly 
diagnose and treat or, whenever possible, prevent these complications.  
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Figure 1. Estimated cumulative proportion survival (Kaplan-Meier curve) 
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Descriptive analysis of the study population 
 
  
 
97 patients 
 
 
24 patients who died 
 
Diagnostic 
 
category, n (%) 
 
ADM 
 
APM 
 
OS 
 
37 (38.1) 
 
35 (36.1) 
 
25 (25.8) 
9 (37.5) 
 
8 (33.3) 
 
7 (29.2) 
Sex, n (%) 
 
Female 
 
Male 
 
 
72 (74.2) 
 
25 (25.8) 
 
 
14 (58.3) 
 
10 (41.7) 
 
Ethnicity, n (%) 
 
Caucasian 
 
Afro-Caribbean 
 
South Asian 
 
Asian 
 
Other 
 
 
62 (63.9) 
 
21 (21.7) 
 
10 (10.3) 
 
3 (3.1) 
 
1 (1) 
 
 
16 (66.7) 
 
5 (20.8) 
 
2 (8.3) 
 
0 (0) 
 
1 (4.2) 
 
 
Age at diagnosis, 
 
mean (SD) 
 
 40.5 (13.2) 41.6 (14.6) 
Age groups 
 
(years), n (%) 
 
< 20 
 
20 – 39 
 
40 – 59 
 
≥60 
 
 
6 (6.2) 
 
44 (45.4) 
 
37 (38.1) 
 
10 (10.3) 
 
 
1 (4.2) 
 
11 (45.8) 
 
8 (33.3) 
 
4 (16.7) 
 
 
Duration of 
 
Symptoms 
 
(months), 
 
median (IQR) 
 
 
6 (9) 
 
(16 missing values) 
6 (5.5) 
 
(3 missing values) 
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Duration of 
 
Symptoms 
 
(months), 
 
groups n (%) 
 
< 3 
 
3 - <9 
 
9 - <18 
 
≥18 
 
 
 
 
26 (26.8) 
 
28 (28.9) 
 
18 (18.5) 
 
9 (9.3) 
 
(16 missing values) 
 
 
 
 
4 (16.7) 
 
12 (50) 
 
5 (20.8) 
 
0 (0) 
 
( 3 missing values) 
 
 
Upper/Lower 
 
limb 
 
involvement, n 
 
(%) 
 
UL+/LL+ 
 
UL-/LL+ 
 
UL-/LL- 
94 (96.9) 
 
1 (1) 
 
2 (2.1) 
22 (91.6) 
 
1 (4.2) 
 
1 (4.2) 
Highest CK, n (%) 
N 
 
N - <2x upper limit 
 
2 - <5x upper limit 
 
5 - <10x upper limit 
 
≥ 10x upper limit 
 
 
 
8 (8.2) 
 
3 (3.1) 
 
10 (10.3) 
 
12 (12.4) 
 
61 (62.9) 
 
(3 missing values) 
 
3 (12.5) 
 
0 (0) 
 
2 (8.3) 
 
3 (12.5) 
 
16 (66.7) 
ANA +, n (%)  
 
47 (48.5) 
 
(1 missing value) 
 
 
14 (58.3) 
 
(1 missing value) 
 
Other 
 
autoantibodies, 
 
n (%) 
Antisynthetase + 
 
SRP + 
 
Mi 2 + 
 
RNP + 
 
 
 
 
22 (22.7) 
 
3 (3.1) 
 
5 (5.2) 
 
13 (13.4) 
 
(2 missing values for 
each antibody) 
 
 
8 (33.3) 
 
0 (0) 
 
1 (4.2) 
 
5 (20.8) 
 
(1 missing value for each antibody) 
 
23 
 
Extramuscular 
 
complications, n 
 
(%) 
 
Cardiac involvement 
 
Lung involvement 
 
Malignancy 
 
Infection 
 
GI involvement 
 
Skin ulcers 
 
Calcinosis 
 
Joint involvement 
 
 
 
24 (24.7) 
 
31 (32) 
 
12 (12.4) 
 
32 (33) 
 
31 (32) 
 
8 (8.2) 
 
7 (7.2) 
 
45 (46.4) 
 
* 
 
 
12 (50) 
 
11 (45.8) 
 
6 (25) 
 
14 (58.3) 
 
8 (33.3) 
 
3 (12.5) 
 
3 (12.5) 
 
8 (33.3) 
 
* 
Treatment, n (%) 
 
 
S 
 
S + 1 IS 
 
S + 2 IS 
 
S + 3 IS 
 
S + ≥4 IS 
 
 
 
7 (7.2) 
 
26 (26.8) 
 
25 (25.8) 
 
11 (11.3) 
 
28 (28.9) 
 
 
3 (12.5) 
 
4 (16.7) 
 
8 (33.3) 
 
4 (16.7) 
 
5 (20.8) 
 
 
Disease course, n 
 
(%) 
 
 
M 
 
RR 
 
CP 
 
35 (36.1) 
 
33 (34) 
 
29 (29.9) 
6 (25) 
 
8 (33.3) 
 
10 (41.7) 
 
Duration of 
 
follow-up 
 
(years), median 
 
(IQR) 
 
 9 (11.5) 10 (8.75) 
 
Table 1. Descriptive analysis of the study population 
SD – standard deviation; IQR – interquartile range; ADM – adult onset dermatomyositis; APM – adult onset 
polymyositis; OS – overlap syndrome; UL+/LL+ - upper and lower limb involvement; UL-/LL+ - only lower limb 
involvement; UL-/LL- - no evidence of proximal weakness; N – normal CK; N - <2x upper limit - CK level 
24 
 
between the upper limit of normal and two times the upper limit of normal; 2 - <5x upper limit - CK level 
between two and five times the upper limit of normal; 5 - <10x upper limit - CK level between five and ten 
times the upper limit of normal; ≥ 10x upper limit - CK level of at least ten times the upper limit of normal; 
GI – gastrointestinal; S – steroids; IS – immunosuppressants; M – monophasic; RR – relapsing and remitting; 
CP – chronic persistent  
* - Data were missing in 3 patients in each category, except for malignancy where we lacked information on 
2 patients 
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Causes of 
 
Death 
 
Lung Cardiac Malignancy Infection Other/uncertain Total 
n (%) 2 (8.3) 4 (16.7) 6 (25) 7 (29.2) 5 (20.8) 
24 
(100) 
Specific 
 
causes, n 
ILD – 2 
 
Myocardial 
 
infarction – 3 
 
Cardiac 
 
involvement*- 
1 
Lung cancer – 1 
 
Hematological (HL) – 2 
 
Gynecological – 2 
 
(1 ovarian, 1 
 
endometrial) 
 
Uncertain - 1 
Pneumonia – 5 
 
Sepsis  – 2 
 
Trauma – 1 
 
GI bleeding – 1 
 
Uncertain - 3 
 
 
Table 2. Causes of death 
ILD – interstitial lung disease; HL – Hodgkin lymphoma; GI – gastrointestinal 
*this patient had heart failure, mitral valvulopathy and a conduction defect 
 
 
 
 
 
 
 
 
 
 
 
 
